|
1
|
Bianchini G, Balko JM, Mayer IA, Sanders
ME and Gianni L: Triple-negative breast cancer: Challenges and
opportunities of a heterogeneous disease. Nat Rev Clin Oncol.
13:674–690. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Collignon J, Lousberg L, Schroeder H and
Jerusalem G: Triple-negative breast cancer: Treatment challenges
and solutions. Breast Cancer (Dove Med Press). 8:93–107.
2016.PubMed/NCBI
|
|
3
|
Kalimutho M, Parsons K, Mittal D, López
JA, Srihari S and Khanna KK: Targeted therapies for triple-negative
breast cancer: Combating a stubborn disease. Trends Pharmacol Sci.
36:822–846. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Prossnitz ER and Barton M: Estrogen
biology: New insights into GPER function and clinical
opportunities. Mol Cell Endocrinol. 389:71–83. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Steiman J, Peralta EA, Louis S and Kamel
O: Biology of the estrogen receptor, GPR30, in triple negative
breast cancer. Am J Surg. 206:698–703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pandey DP, Lappano R, Albanito L, Madeo A,
Maggiolini M and Picard D: Estrogenic GPR30 signalling induces
proliferation and migration of breast cancer cells through CTGF.
EMBO J. 28:523–532. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Girgert R, Emons G and Gründker C:
Inactivation of GPR30 reduces growth of triple-negative breast
cancer cells: Possible application in targeted therapy. Breast
Cancer Res Treat. 134:199–205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu T, Liu M, Luo H, Wu C, Tang X, Tang S,
Hu P, Yan Y, Wang Z and Tu G: GPER mediates enhanced cell viability
and motility via non-genomic signaling induced by 17β-estradiol in
triple-negative breast cancer cells. J Steroid Biochem Mol Biol.
143:392–403. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Girgert R, Emons G and Gründker C:
Inhibition of GPR30 by estriol prevents growth stimulation of
triple-negative breast cancer cells by 17β-estradiol. BMC Cancer.
14:9352014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lappano R, Pisano A and Maggiolini M: GPER
function in breast cancer: An Overview. Front Endocrinol
(Lausanne). 5:662014.PubMed/NCBI
|
|
11
|
Hung AY and Sheng M: PDZ domains:
Structural modules for protein complex assembly. J Biol Chem.
277:5699–5702. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Meng R, Qin Q, Xiong Y, Wang Y, Zheng J,
Zhao Y, Tao T, Wang Q, Liu H, Wang S, et al: NHERF1, a novel GPER
associated protein, increases stability and activation of GPER in
ER-positive breast cancer. Oncotarget. 7:54983–54997.
2016.PubMed/NCBI
|
|
13
|
Molina JR, Agarwal NK, Morales FC, Hayashi
Y, Aldape KD, Cote G and Georgescu MM: PTEN, NHERF1 and PHLPP form
a tumor suppressor network that is disabled in glioblastoma.
Oncogene. 31:1264–1274. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hayashi Y, Molina JR, Hamilton SR and
Georgescu MM: NHERF1/EBP50 is a new marker in colorectal cancer.
Neoplasia. 12:1013–1022. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bellizzi A, Malfettone A, Cardone RA and
Mangia A: NHERF1/EBP50 in breast cancer: Clinical perspectives.
Breast Care (Basel). 5:86–90. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Song J, Bai J, Yang W, Gabrielson EW, Chan
DW and Zhang Z: Expression and clinicopathological significance of
oestrogen-responsive ezrin-radixin-moesin-binding phosphoprotein 50
in breast cancer. Histopathology. 51:40–53. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ediger TR, Kraus WL, Weinman EJ and
Katzenellenbogen BS: Estrogen receptor regulation of the Na+/H+
exchange regulatory factor. Endocrinology. 140:2976–2982. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stemmer-Rachamimov AO, Wiederhold T,
Nielsen GP, James M, Pinney-Michalowski D, Roy JE, Cohen WA, Ramesh
V and Louis DN: NHE-RF, a merlin-interacting protein, is primarily
expressed in luminal epithelia, proliferative endometrium, and
estrogen receptor-positive breast carcinomas. Am J Pathol.
158:57–62. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yao W, Feng D, Bian W, Yang L, Li Y, Yang
Z, Xiong Y, Zheng J, Zhai R and He J: EBP50 inhibits EGF-induced
breast cancer cell proliferation by blocking EGFR phosphorylation.
Amino Acids. 43:2027–2035. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Saponaro C, Malfettone A, DellEndice TS,
Brunetti AE, Achimas-Cadariu P, Paradiso A and Mangia A: The
prognostic value of the Na+/H+ exchanger regulatory factor 1
(NHERF1) protein in cancer. Cancer Biomark. 14:177–184. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dai JL, Wang L, Sahin AA, Broemeling LD,
Schutte M and Pan Y: NHERF (Na+/H+ exchanger regulatory factor)
gene mutations in human breast cancer. Oncogene. 23:8681–8687.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barton M: Not lost in translation:
Emerging clinical importance of the G protein-coupled estrogen
receptor GPER. Steroids. 111:37–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jacenik D, Cygankiewicz AI and Krajewska
WM: The G protein-coupled estrogen receptor as a modulator of
neoplastic transformation. Mol Cell Endocrinol. 429:10–18. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Filardo EJ, Graeber CT, Quinn JA, Resnick
MB, Giri D, DeLellis RA, Steinhoff MM and Sabo E: Distribution of
GPR30, a seven membrane-spanning estrogen receptor, in primary
breast cancer and its association with clinicopathologic
determinants of tumor progression. Clin Cancer Res. 12:6359–6366.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Srivastava DP and Evans PD: G-protein
oestrogen receptor 1Trials and tribulations of a membrane oestrogen
receptor. J Neuroendocrinol. 25:1219–1230. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Weißenborn C, Ignatov T, Ochel HJ, Costa
SD, Zenclussen AC, Ignatova Z and Ignatov A: GPER functions as a
tumor suppressor in triple-negative breast cancer cells. J Cancer
Res Clin Oncol. 140:713–723. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wei W, Chen ZJ, Zhang KS, Yang XL, Wu YM,
Chen XH, Huang HB, Liu HL, Cai SH, Du J, et al: The activation of G
protein-coupled receptor 30 (GPR30) inhibits proliferation of
estrogen receptor-negative breast cancer cells in vitro and in
vivo. Cell Death Dis. 5:e14282014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pan Y, Wang L and Dai JL: Suppression of
breast cancer cell growth by Na+/H+ exchanger regulatory factor 1
(NHERF1). Breast Cancer Res. 8:R632006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ardura JA and Friedman PA: Regulation of G
protein-coupled receptor function by Na+/H+ exchange regulatory
factors. Pharmacol Rev. 63:882–900. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lazar CS, Cresson CM, Lauffenburger DA and
Gill GN: The Na+/H+ exchanger regulatory factor stabilizes
epidermal growth factor receptors at the cell surface. Mol Biol
Cell. 15:5470–5480. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Filardo EJ: Epidermal growth factor
receptor (EGFR) transactivation by estrogen via the
G-protein-coupled receptor, GPR30: A novel signaling pathway with
potential significance for breast cancer. J Steroid Biochem Mol
Biol. 80:231–238. 2002. View Article : Google Scholar : PubMed/NCBI
|
